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Severely burned patients have altered drug pharmacokinetics (PKs), but it is unclear how different they are from those in other
critically ill patient groups. The aim of the present study was to compare the population pharmacokinetics of micafungin in the
plasma and burn eschar of severely burned patients with those of micafungin in the plasma and peritoneal fluid of postsurgical
critically ill patients with intra-abdominal infection. Fifteen burn patients were compared with 10 patients with intra-abdominal
infection; all patients were treated with 100 to 150 mg/day of micafungin. Micafungin concentrations in serial blood, peritoneal
fluid, and burn tissue samples were determined and were subjected to a population pharmacokinetic analysis. The probability of
target attainment was calculated using area under the concentration-time curve from 0 to 24 h/MIC cutoffs of 285 for Candida
parapsilosis and 3,000 for non-parapsilosis Candida spp. by Monte Carlo simulations. Twenty-five patients (18 males; median
age, 50 years; age range, 38 to 67 years; median total body surface area burned, 50%; range of total body surface area burned, 35
to 65%) were included. A three-compartment model described the data, and only the rate constant for the drug distribution
from the tissue fluid to the central compartment was statistically significantly different between the burn and intra-abdominal
infection patients (0.47 0.47 versus 0.15 0.06 h1, respectively; P< 0.05). Most patients would achieve plasma PK/pharma-
codynamic (PD) targets of 90% for non-parapsilosis Candida spp. and C. parapsilosis with MICs of 0.008 and 0.064 mg/liter,
respectively, for doses of 100 mg daily and 150 mg daily. The PKs of micafungin were not significantly different between burn
patients and intra-abdominal infection patients. After the first dose, micafungin at 100 mg/day achieved the PK/PD targets in
plasma for MIC values of<0.008 mg/liter and<0.064 mg/liter for non-parapsilosis Candida spp. and Candida parapsilosis spe-
cies, respectively.
The management of patients with severe burn injuries requirescritical care in specialized units with equipment, supplies, and
personnel for intensivemonitoring and life-sustaining organ sup-
port until the patients recover and the wounds are healed. Al-
though improvements in supportive care have led to lower
mortality rates, infections, especially wound fungal infections,
continue to be a life-threatening complication (1, 2). Burn pa-
tients are a population at a significant risk of opportunistic infec-
tions (3), and burn wound infections are caused by fungi in 20 to
25% of the cases (4). Furthermore, in patients that require at least
3 weeks of critical care unit admission, Candida spp. become the
most common cause of bloodstream infections (5). Among criti-
cally ill patients with severe burn injuries, infections caused by
Candida spp. are increasingly common (6) and are associatedwith
high rates of morbidity and mortality (7).
Due to the high burden of fungal infections, initiation of early
and appropriate antifungal therapy that achieves optimal concen-
trations in plasma and at the infection site, such as the burn eschar,
is essential to ensure clinical efficacy (8). In the selection of possi-
ble antifungal agents, the dose should be reviewed to ensure suf-
ficient drug distribution to the infection site. Candida spp. can
disseminate to pharmacologically protected body sites, such as the
burn eschar, and an antifungal with the ability to penetrate these
tissues should be used (9). Critically ill patients with severe burn
injuries may present with various pathophysiologies (burns with
various sizes and depths, sepsis, hypoalbuminemia, altered capil-
lary permeability, altered renal function, various degrees of hydra-
tion, and the need for renal replacement therapies) that can sig-
nificantly alter antifungal pharmacokinetics (PKs) (10). A high
interindividual variability in the PKs of fluconazole, anidulafun-
gin, caspofungin, and micafungin has been observed in this pop-
ulation (11, 12).
The echinocandins represent the newest class of antifungals
used to treat Candida infections. Micafungin exhibits a concen-
tration-dependent fungicidal activity (13) and has very lowMICs
that are similar formostCandida spp., typically ranging from 0.06
to 0.12 mg/liter (14). It has been approved for use in Europe and
the United States for the treatment of invasive candidiasis, includ-
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ing candidemia (15). Only limited data on the PKs of antifungals
in critically ill patients with burn injuries are available, and there
are no specific dosage recommendations for this patient popula-
tion (16–20). It is also unknown whether the PKs in burn patients
are in fact different from those in other critically ill patient groups,
which may mean that burn patients need their own dosing regi-
mens.
In this context, new PK studies are needed to determine
whether therapeutic concentrations in plasma and the burn eschar
can be achieved with the recommended doses of micafungin to
determine whether patients with severe burn injuries require
doses different from those required by other critically ill patient
groups.
The aim of this study was to compare the infection site popu-
lation PKs of micafungin in critically ill patients with severe burn
injuries with those in patients with intra-abdominal infections
(IAIs). Furthermore, we aimed to use the final PK model to per-
form Monte Carlo dosing simulations to recommend optimized
doses for these patients.
MATERIALS AND METHODS
Study design and population. This was a prospective PK study in which
critically ill adult patients with severe burn injuries were compared with
patients with nosocomial peritonitis and a proven or suspected intra-
abdominal fungal infection. The patients were admitted to the BurnUnit/
Intensive Care Medicine Service, La Paz University Hospital/IdiPAZ In-
stitute for Health Research (Madrid, Spain), and the Anesthesiology and
Surgical Critical Care Department, Hospital del Mar (Barcelona, Spain),
from April 2013 to January 2015.
The study protocol was approved by the Ethics Committee of the La
Paz University Hospital (Madrid, Spain) and the Ethics Committee of the
Hospital del Mar (Barcelona, Spain). Written informed consent was ob-
tained from the patient (or his or her relatives, if the patient was unable to
provide consent due to his or her critical condition) before study inclu-
sion.
The inclusion criteria were an age of 18 years and a diagnosis of a
severe burn injury or postsurgical nosocomial peritonitis due to anasto-
motic dehiscence and, in both cases, a clinical indication for micafungin
therapy. The exclusion criteria were underweight (body mass index
[BMI],19 kg/m2) ormorbid obesity (BMI,40 kg/m2), previous treat-
ment with micafungin, receipt of renal replacement therapy, a previous
kidney transplant, or hepatic cirrhosis.
In all patients included, the following demographic and clinical data
were recorded: age, gender, weight, BMI, sequential organ failure assess-
ment (SOFA) score, percentage of total body surface area (TBSA) burned,
full thickness (FT) burn, the abbreviated burn severity index (ABSI) (21),
the Mannheim peritonitis index, data on treatment with micafungin, the
serum creatinine (SCr) concentration at the first day of micafungin ther-
apy, the number of days from admission to the start of micafungin, the
risk for invasive candidiasis (Candida score), microbiological data, and
crude mortality.
The potential relationship between the concentrations of micafungin
in plasma, burn eschar tissue, and peritoneal fluid and different clinical
and laboratory parameters was assessed. All patients with postsurgical
intra-abdominal infection had a peritoneal catheter in situ to drain in-
flammatory exudate as part of standard therapy.
Micafungin dosing. All patients were treated with 100 to 150 mg/day
of micafungin (Astellas Pharma S.A., Spain) for a proven or suspected
fungal infection.Micafunginwas diluted in 100ml isotonic saline solution
and infused over 60 min.
Blood, peritoneal fluid, and burn tissue sample collection. Blood
samples were drawn on day 1 (after the first dose) and on day 3 or 4 of
treatment (when the steady state had presumably been achieved) just
before the initiation of micafungin (predose) and at different times (1, 3,
5, 8, 18, and 24 h) thereafter. In some burn patients, on day 5 of treatment,
additional blood samples were obtained just before the initiation of mi-
cafungin treatment (predose) and at 1 h thereafter.
Fresh peritoneal fluid samples (1ml) were drained by use of a vacuum
suction system simultaneously with each blood sample, when possible.
Tissue samples from the burn eschar were obtained on day 4 or 5 of
micafungin treatment at different times after the start of the micafungin
infusion: between 1 and 3 h in some patients and at 24 h in others. Tissue
samples were excised from representative lesions in areas with third-de-
gree burns.
Blood samples were collected in heparinized tubes and immediately
centrifuged (at 3,000 g for 10 min at 4°C), and burn eschar tissue and
peritoneal fluid samples were collected in a tubewithout any additives. All
samples were stored at80°C until analysis.
Analytical method. Total micafungin concentrations in plasma and
tissues were determined by a high-performance liquid chromatography
(HPLC) method (22) with minor modifications. Briefly, frozen plasma,
tissue, or peritoneal fluid samples were thawed and protected from light.
Protein was extracted from the blood and peritoneal fluid samples. After
centrifugation at 4°C, the supernatant (50 l) was directly injected into
the HPLC column. Tissue specimens were defrosted, weighed, and ho-
mogenized with water (1:4, vol/wt) for 10 min using a high-speed tissue
homogenizer. The homogenates were incubated for 10 min at 4°C and
then centrifuged at 14,000 g for 5 min.
A Waters Sunfire C18 analytical column (4.6 mm by 150 mm) was
used, and the mobile phase was a mixture of 0.05 M ammonium phos-
phate buffer with acetonitrile. The injection volume of the samples was 50
l. The UV absorbance for the detection of micafungin was set at 273 nm,
and the chromatographic run time was 15 min. Quantification of the
chromatogram was accomplished using the external standard method,
and linear calibration curves were calculated from the peak areas of mica-
fungin compared with the peak area of the external standard by spiking
drug-free human serum andwater with standard solutions ofmicafungin.
The assay showed good linearity over the concentration range of 0.2 to 30
mg/liter for micafungin in plasma and 0.05 to 10 mg/liter for micafungin
inwater. The limits of detection and quantificationwere 0.05mg/liter and
0.2 mg/liter, respectively, for plasma and 0.02 mg/liter and 0.1 mg/liter,
respectively, for the other specimens (peritoneal fluid and burn tissue).
Population pharmacokinetic modeling. Data from both burn and
intra-abdominal infection patients were comodeled. Two- and three-
compartment models were developed with the nonparametric adaptive
grid (NPAG) algorithm within the Pmetrics package for R (Los Angeles,
CA) (23, 24). Elimination from the central compartment and the inter-
compartmental distribution into the peritoneal fluid, burn tissue, and
other compartments were modeled as first-order processes using differ-
ential equations. Estimates of assay error were included in the modeling
process, and both gamma and lambda error models were tested. The
area under the concentration-time curve from 0 to 24 h (AUC0–24) for
plasma, peritoneal fluid, and burn tissue was calculated using the
Pmetrics package.
Population pharmacokinetic covariate screening. Covariate model
building using various clinical and demographic descriptors, including
sex, body weight, and the presence of burns, was performed in a stepwise
fashion with forward inclusion based upon model selection criteria. If
inclusion of the covariate resulted in a statistically significant improve-
ment in the log likelihood values and/or improved the goodness-of-fit
plots, then it was supported for inclusion.
Model diagnostics. Goodness of fit was assessed by linear regression
(intercept, close to zero; slope, close to 1) of the observed versus popula-
tion and individual predicted concentrations and calculation of the coef-
ficient of determination of the linear regression and log-likelihood values.
Evaluation of the predictive performance was based on the mean predic-
tion error (bias) and the mean bias-adjusted squared prediction error
(imprecision) of the population and individual prediction models for the
plasma, peritoneal fluid, and burn tissue compartments. A visual predic-
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tive check (VPC) using 1,000 simulations was used for further model
evaluation. A statistically significant improvement in the log likelihood
value (P 0.05) was required for amore complexmodel to be supported.
Monte Carlo simulations of plasma concentrations and probability
of target attainment. Various Monte Carlo simulations of plasma mica-
fungin concentrations for a hypothetical patient cohort (n 1,000) were
employed using the Pmetrics package to calculate the total AUC0–24/MIC
for various MIC values (0.002 to 4 mg/liter). Intravenous doses of mica-
fungin of 100 mg daily, 150 mg daily, and 200 mg daily for 0 to 24 h were
simulated, with target micafungin exposures being defined according to
total plasma AUC0–24/MIC targets of 3,000 for non-parapsilosis Candida
spp. and 285 for Candida parapsilosis (25). A priori, a dosing regimen was
considered successful if the probability of target attainment was90%.
Statistical analysis. Descriptive statistics included absolute and rela-
tive frequencies for categorical variables, means and 95% confidence in-
tervals (CIs) for continuous quantitative variables, and medians and
ranges for ordinal quantitative variables. For the analyses, a 2-sided P
value of 0.05 was considered statistically significant. The Statistical
Package for the Social Sciences (SPSS;, version 13.0) was used throughout.
RESULTS
During the study period, 15 critically ill patients with severe burn
injuries were included, and these patients were compared with 10
postsurgical critically ill patients with intra-abdominal infections.
Each patient had a proven or a suspected fungal infection. The
demographic and clinical data for the burn patients and the pa-
tients with intra-abdominal infection are detailed in Table 1. The
burn patients were younger and had a higher total body weight
than patients with intra-abdominal infection. No differences in
any other clinical characteristics were observed. In the group of
burn patients, 13/15 (86.7%) presented a TBSA burned30%. In
all burn patients, themedian time from the time of admission due
to injury to the start of micafungin treatment was48 h.
The median daily dose of micafungin normalized according to
body weight was 1.25 mg/kg (interquartile range [IQR], 1.00 to
1.80 mg/kg) for the burn injury patients and 1.5 mg/kg (IQR, 1.4
to 1.7 mg/kg) for the patients with intra-abdominal infection. No
differences in the micafungin dose normalized according to body
weight, the severity status (measured by the SOFA score), or the
serum creatinine concentration were observed between the burn
and intra-abdominal infection patients (P  0.461, 0.770, and
0.643, respectively). One (1/15, 6.7%) burn patient and 4 (4/10,
40%) patients with intra-abdominal infection were found by cul-
ture to harborCandida albicans, and in all patients, the isolate was
susceptible to micafungin (MIC value 0.016mg/liter) (24). Mi-
cafungin was well tolerated by all patients, with no adverse effects
being observed. The crude mortality rate was 36% (9/25 patients;
7 burn patients and 2 patients with intra-abdominal infections).
Micafungin concentrations. Figure 1 shows the micafungin
concentrations observed in plasma and tissue for both patient
groups. On day 1, the median AUC0–24 for plasma was not signif-
icantly different between the burn patients (48.3mg · h/liter; IQR,
37.7 to 55.8 mg · h/liter) and the intra-abdominal infection pa-
tients (51.4 mg · h/liter; IQR, 44.6 to 56.4 mg · h/liter). The differ-
ence in the AUC0–24 for tissue fluid was numerically different
between the groups but was not statistically significantly different:
3.8 mg · h/liter (IQR, 3.3 to 17.4 mg · h/liter) for burn tissue and
15.6mg · h/liter (IQR, 11.8 to 17.2mg · h/liter) for peritoneal fluid
(P  0.08). This corresponded to a median AUC0–24 for tissue
fluid/AUC0–24 for plasma ratio of 0.15 (IQR, 0.06 to 0.38) for the
burn patients and 0.29 (IQR, 0.24 to 0.37) for the intra-abdominal
infection patients. Penetration into both tissue fluids was not sta-
tistically significantly different (P 0.14).
Micafungin concentrations in burn eschar. Themedian con-
centration of micafungin in burn eschar tissue was 0.7 g/g of
tissue (IQR, 0.3 to 1.2g/g of tissue). In two patients, the concen-
tration of micafungin in the burn eschar was below the limit of
quantification. The concentrations of micafungin in burn eschar
tissues were not linearly correlated with any of these patients’ fac-
tors:micafungin daily dose adjusted according to bodyweight, the
TABLE 1 Clinical and demographic characteristics of burn patients and intra-abdominal infection patients
Characteristic
Value(s) for:
P valueBurn patients (n 15) Intra-abdominal infection patients (n 10)
Median (IQR) age (yr) 43 (32.0–49.5) 72 (54–77.8) 0.015
No. (%) male patients 12 (80) 6 (60) NS
Median (IQR):
BW (kg) 80.0 (75.0–87.5) 65 (60.3–73.8) 0.041
BMI (kg/m2) 26.1 (24.6–27.7) 23.1 (21.5–24.0) NS
SCr concnb (mg/dl) 0.82 (0.62–1.06) 0.96 (0.62–1.49) NS
TBSA burned (%) 50 (35.0–65.0)
FT burn (%) 40 (31–57)
ABSI 9.0 (8.0–10.5)
SOFA scoreb 5.0 (3.0–6.0) 5 (1.5–7.5) NS
MPI 26 (19–28.5)
Micafungin dose (mg/kg BW) 1.3 (1.2–1.8) 1.5 (1.3–1.7) NS
No. of days from admission to start of micafungin therapy 12 (10–15)
Candida score 3 (2–4) 4 (4–4) NS
No. (%) of patients with:
Candidemia 1 (6.7) 4 (40) NS
Crude mortality or nonsurvivors 7 (46.7) 2 (20) NS
a F, female; M, male; BW, body weight; BMI, body mass index; SCr, serum creatinine; TBSA, total body surface area; FT, full thickness; ABSI, abbreviated burn severity index;
SOFA, sequential organ failure assessment; MPI, Mannheim peritonitis index; IQR, interquartile range; NS, no significant difference.
b At the beginning of micafungin therapy.
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size of the burn (percentage of TBSA burned), or severity status
(ABSI or SOFA score). A correlation between the concentrations
of micafungin in plasma and those in burned tissues was also not
found.
Pharmacokinetic model building. The time course of the
plasma and tissue fluid concentrations of micafungin was best
described by a three-compartment linear model (Fig. 2). This
model included a zero-order input of drug into the central com-
partment. No covariates were found to be statistically significant
or improved the fit of the model.
The mean standard deviation (SD) population PK parame-
ter estimates from the final model are shown in Table 2.When the
PK parameters between the burn and intra-abdominal infection
patients were compared, no statistically significant differences
were observed, except for the rate constant for the drug distribu-
tion from the tissue fluid to the central compartment (ktc), which
was 3 times higher in burn patients than in the patients with intra-
abdominal infection (median values, 0.47 h1 and 0.15 h1, re-
spectively).
The diagnostic plots confirmed that the goodness of fit of the
model was acceptable, as shown in Fig. 3 (observed versus popu-
lation and individual predicted concentrations) and in Fig. 4a
(VPC of plasma data) and Fig. 4b (VPC of tissue data). The final
model was used for dosing simulations.
Probability of target attainment. The probabilities of target
attainment for the simulated targets on day 1 (0 to 24 h) in plasma
for a range of micafungin doses against the MIC distributions for
Candida spp. and C. parapsilosis are shown in Tables 3 and 4,
respectively. Only day 1 was simulated because no differences in
PKs were observed between sampling occasions.
In the simulations, the plasma PK/pharmacodynamic (PD)
targets were achievedwith a 90%probability forCandida spp. and
C. parapsilosis with MICs of 0.008 and 0.064, respectively, for the
100-mg and 150-mg daily doses. The 200-mg daily dose achieved
these PK/PD targets at MICs of 0.016 mg/liter and 0.125 mg/liter
for Candida spp. and C. parapsilosis, respectively. It should be
noted that these simulations did not discriminate between the
burn and peritonitis patients because the covariate analysis did
not identify significant differences between these twopopulations.
DISCUSSION
This is the first study ofmicafungin population PKs in plasma and
burn eschar tissue in critically ill patientswith severe burn injuries.
We elected to compare the PKs of micafungin in patients with
burns to those in patients with intra-abdominal infections be-
cause, althoughmany clinicians would consider them to be differ-
ent critically ill subpopulations, it is still recommended that both
groups receive the same drug doses. Therefore, we hypothesized
that if we determined any significant differences in PKs between
these groups, it may lead to different dosing recommendations for
the two subpopulations.When the PK parameter estimates for the
burn patients were compared to those for the intra-abdominal
infection patients, no statistically significant differences were ob-
served between the groups, except for the rate constant for the
drug distribution from the tissue fluid to central compartment
(ktc) (0.47 0.47 versus 0.15 0.06 h
1, respectively; P 0.05).
Therefore, the use of different dosing regimens for the individual
groups is not supported by these data. We observed that the stan-
dard dose of micafungin, 100 mg/day, achieves optimal PK/PD
targets in plasma for MIC values of 0.008 mg/liter and 0.064
FIG 2 Structural pharmacokinetic model for micafungin in critically ill pa-
tients with intraperitoneal drains in situ. The model was linear and contained
volume compartments for the central compartment (plasma; Vcentral), the
peritoneal fluid compartment, and the peripheral compartment. Abbrevia-
tions: IV, intravenous; kcp, rate constant for the drug distribution from the
central to the peripheral compartment; kpc, rate constant for the drug distri-
bution from the peripheral to the central compartment; Vcentral, volume of
distribution of the central compartment; kct, rate constant for the drug distri-
bution from the central to the tissue fluid compartment; ktc, rate constant for
the drug distribution from the tissue fluid to the central compartment; CL,
clearance.
FIG 1 Observedmicafungin concentrations in plasma (black symbols) and tissue fluid (red symbols). Posterior predictions of the concentration-time curve for
plasma (black) and tissue fluid (red) are denoted with solid lines (n 25 patients).
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mg/liter for non-parapsilosis Candida spp. and Candida parapsi-
losis, respectively. By increasing the dose to 200 mg/day, the opti-
mal PK/PD targets in plasma could be achieved for MIC cutoff
values that are twofold higher (0.016 mg/liter and 0.125 mg/liter,
respectively).
In this study, no differences in the PKs of micafungin were
observed between the two populations of critically ill patients
studied, even though the burn patients had a greater body weight
than those with intra-abdominal infection. The plasma exposure
to micafungin in our whole cohort (median AUC0–24 for plasma
on day 1, 48.3 mg · h/liter [IQR, 37.7 to 55.8 mg · h/liter] and 51.4
mg · h/liter [IQR, 44.6 to 56.4 mg · h/liter] in burn patients and
patients with intra-abdominal infections, respectively) was simi-
lar to that achieved in patients with invasive candidiasis and can-
didemia (mean SD AUC0–24, 56.6 30.1 mg · h/liter) (25) but
slightly lower than that reported in other critically ill patients (me-
dianAUC0–24, 78.6mg · h/liter; IQR, 65.3 to 94.1mg · h/liter) (11).
Regarding the PK parameters, the estimated clearance for all pa-
tients (burn and intra-abdominal infection patients) was similar
to that reported in patients with invasive candidiasis and candi-
demia (1.44  0.73 liters/h) (26) and also in other critically ill
patients (1.3 1.1 to 1.5 liters/h) (12).
Information describing the PKs of antifungals in critically ill
patients is limited, especially for echinocandins, which is of con-
cern, given that it has been widely described how critical illness
may significantly alter the PKs of many agents and compromise
their efficacy (12, 27, 28). A prospective, multicenter study of the
PKs of different antifungals that enrolled patients from 68 inten-
sive care units across Europe reported a considerable interindi-
vidual variability in the PKs of caspofungin and anidulafungin,
TABLE 2 Parameter estimates for micafungin from the final three-compartment population PK modela
Parameter
Mean SD value for:
Coefficient of variation MedianBurn patients (n 15) Intra-abdominal infection patients (n 10) All patients (n 25)
CL (liters/h) 1.61 0.62 1.09 0.72 1.38 0.70 50.93 1.33
Vcentral (liters) 6.07 2.77 5.85 1.02 5.87 2.44 41.55 5.21
kct (h
1) 0.59 0.31 0.42 0.35 0.43 0.34 77.37 0.40
ktc (h
1) 0.47 0.47 0.15 0.06 0.32 0.42 131.47 0.17
kcp (h
1) 16.87 11.93 24.98 8.03 19.93 11.07 55.55 25.06
kpc (h
1) 9.93 6.02 11.95 4.02 9.90 5.64 57.00 8.90
a Data are presented as the mean SD for burn patients only, intra-abdominal infection patients only, and all patients combined and as the coefficient of variation and median for
all patients. Boldface data indicate a statistically significant difference (P 0.05) between the burn and intra-abdominal infection patients. CL, clearance; Vcentral, volume of
distribution of the central compartment; kct, rate constant for the drug distribution from the central to tissue fluid compartment; ktc, rate constant for the drug distribution from
the tissue fluid to the central compartment; kcp, rate constant for the drug distribution from the central to the peripheral compartment; kpc, rate constant for the drug distribution
from the peripheral to the central compartment.
FIG 3 Diagnostic plots for the final covariate model. (Top) Observed versus population predicted concentrations and individual predicted concentrations in
plasma; (bottom) observed versus population predicted concentrations and individual predicted concentrations in tissue fluid. Red points, data for patients with
intra-abdominal infections; black points, data for burn patients.
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and the authors suggested the need to optimize the doses to reduce
this variability (11).Unfortunately, patients treatedwithmicafun-
gin were not included in that study.
In the critically ill subpopulation of severely burned patients,
data on the PKs of echinocandins are even scarcer (16, 18, 20). To
date, we are aware of only 3 reports of the PKs of echinocandins in
patients with severe burn injuries (16, 20, 29). Sasaki et al. per-
formed a study of the PKs of 200 to 300 mg/day of micafungin in
6 patients with severe burns and reported plasma concentrations
much higher than those observed in our study (16). However, that
study administered a dose that was 2 to 3 times higher than the
dose administered to our patients. Furthermore, the amount of
FIG 4 Visual predictive check (n  1,000 simulations) of plasma data (a) and tissue data (b) from the final covariate model showing that the population
pharmacokinetic model has adequate performance; the raw data for individual patients are shown as dots, and the continuous lines represent the 5th, 25th, 50th,
75th, and 95th percentiles of the simulations.
TABLE 3 Probability of target attainment using a AUC0–24/MIC target
of 3,000 for non-parapsilosis Candida spp. for different micafungin
dosing regimens
MIC (mg/liter)
Probability of target attainment for daily micafungin
dose ofa:
100 mg daily 150 mg daily 200 mg daily
0.001 0.999 0.999 0.999
0.002 0.998 0.998 0.999
0.004 0.994 0.998 0.998
0.008 0.975 0.992 0.994
0.016 0.58 0.899 0.975
0.032 0.037 0.253 0.58
0.064 0.002 0.009 0.037
0.125 0 0.001 0.002
0.25 0 0 0
a The boldface data represent dosing regimens that achieved a90% probability of
target attainment.
TABLE 4 Probability of target attainment using a AUC0–24/MIC target
of 285 for Candida parapsilosis for different micafungin dosing regimens
MIC (mg/liter)
Probability of target attainment for daily micafungin
dose ofa:
100 mg daily 150 mg daily 200 mg daily
0.001 1 1 1
0.002 1 1 1
0.004 1 1 1
0.008 0.999 0.999 1
0.016 0.998 0.999 0.999
0.032 0.997 0.998 0.998
0.064 0.99 0.994 0.997
0.125 0.845 0.975 0.99
0.25 0.169 0.589 0.845
0.5 0.005 0.038 0.169
1 0 0.002 0.005
2 0 0 0
a The boldface data represent dosing regimens that achieved a90% probability of
target attainment.
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time that elapsed between the start of micafungin therapy after
injurywas shorter (mean times, 7.7 days in the previous study [16]
compared to 16.2 days in the present study). Indeed, itmay be that
the hypermetabolic phase (beyond 48 h after the burn injury),
which can affect the intensity of physiological changes over differ-
ent days, contributed to the altered and highly variable PKs (11).
This lower level of exposure to micafungin observed in our
patients has also been reported for other antifungals in burn pa-
tients (17, 29, 30). The PKs of caspofungin were assessed in two
burn patients, and the exposure was similar to that observed in
healthy volunteers in one patient, but it was 50% lower in the
other (29). Unfortunately, the concentrations in burn eschar tis-
sue were not reported in that study. Another report described the
PKs of fluconazole in nine patients with extensive burns injuries
and demonstrated that the patients had higher clearances and vol-
umes of distribution than healthy subjects (17).
An important limitation of our study might prevent a more
accurate determination of the micafungin concentrations in
burned tissues. That is, the burn eschar tissue homogenate com-
bines intra- and extracellular material, and given that echinocan-
dins do not penetrate intracellularly well, the current results may
underestimate the interstitial fluid concentrations of micafungin.
Additionally, tissue samples from eschars had different degrees of
burns and were obtained at different times after the start of the
micafungin infusion, which may have contributed to the variabil-
ity of the observed concentrations.
Micafungin showed a low level of penetration into the eschars,
with a median AUC0–24 for tissue fluid/AUC0–24 for plasma ratio
of 0.15 (IQR, 0.06 to 0.38). To our knowledge, only one previous
paper has reported the penetration of micafungin into burn tis-
sues, but it was performedwith only 3 patients and reported a very
high interindividual variability in the peak concentration ofmica-
fungin in burn eschar (mean SD value after repeated adminis-
tration, 6.65 7.22 g/ml) (20). However, in the previous study,
the concentration of micafungin was expressed in different units
(micrograms per milliliter instead of micrograms per gram of tis-
sue), which makes any comparison with our results difficult.
Ensuring effective dosing likely maximizes the likelihood of
clinical cure of invasive fungal infections in critically ill patients
(31). AUC/MIC ratios of 3,000 and 285 for micafungin have been
associated with positive therapeutic outcomes in a population
pharmacokinetic/pharmacodynamicmodel of patients with inva-
sive candidiasis or candidemia caused byC. albicans andC. parap-
silosis, respectively (25). Micafungin at a dose of 100 to 150 mg
would achieve a PK/PD target in plasma for non-parapsilosis Can-
dida spp. and Candida parapsilosis species with MIC values
of0.008 mg/liter and0.064 mg/liter, respectively. By increas-
ing the dose to 200mg/day, these targets would be achieved for the
current EUCAST susceptibility breakpoint for C. albicans (0.016
mg/liter) but not forC. glabrata (0.03mg/liter) andC. parapsilosis
(2 mg/liter) (32).
This study has other limitations that we would like to declare.
First, this was a small study which may not have been able to
describe the true PK variability in this population. Nevertheless,
this is the first population PK study of antifungals in severely
burned patients. Second, we compared the exposure to micafun-
gin between two tissue fluids with different characteristics, such as
inflammatory status and protein concentrations, what could
probably have influenced the degree of penetration of this anti-
fungal. Finally, we could not correlate PK/PD target attainment
with the patients’ clinical response due to the low number of pa-
tients with a microbiologically confirmed infection.
In conclusion, this is the first population study of the PKs of
micafungin in plasma and burn eschar tissue in critically ill pa-
tients with severe burn injuries, which were compared with the
PKs of micafungin in patients with intra-abdominal infections.
The PKs of micafungin in this subpopulation did not seem to
differ from those in other critically ill patients, such as those with
intra-abdominal infection. In burn patients, the level of penetra-
tion ofmicafungin into the burn eschar that was observed was low
and showed a high level of interindividual variability. We found
that micafungin at 100 to 150 mg/day achieved suboptimal
exposure in plasma for the treatment of fungal infections
caused by Candida strains by use of the current susceptibility
breakpoints (1).
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